IGF-1 DES
IGF-1 DES (des(1-3)IGF-1)
A truncated, ten-times-more-potent form of IGF-1 with a very short half-life designed for site-specific muscle targeting.
IGF-1 DES, also known as des(1-3)IGF-1, is a truncated form of insulin-like growth factor 1. The name refers to the removal of the first three amino acids from the N-terminus of the original IGF-1 molecule. Where native IGF-1 contains 70 amino acids, IGF-1 DES contains only 67. This seemingly small modification results in a peptide that is approximately 10 times more potent than regular IGF-1 at stimulating cell growth and proliferation.
The increased potency comes from a critical structural change: the absence of glutamate at position 3. This missing amino acid dramatically reduces binding to IGF binding proteins (IGFBPs), which are the regulatory proteins that normally limit how much IGF-1 is available to interact with receptors. With almost no binding to IGFBPs, nearly all of the administered IGF-1 DES remains free and biologically active, rather than being tied up and inactive as most natural IGF-1 is.
IGF-1 DES is not purely a synthetic creation. It occurs naturally in the human body and has been isolated from human brain tissue, bovine colostrum, and porcine uterine tissue. The peptide likely results from post-translational cleavage of intact IGF-1. Its half-life is approximately 20 to 30 minutes, which contrasts sharply with IGF-1 LR3's 20 to 30 hour half-life. This short duration makes IGF-1 DES more suitable for localized, site-specific applications rather than systemic effects. It is not FDA approved and is prohibited by WADA.
How It Works
IGF-1 DES exerts its effects by binding to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor found on many cell types throughout the body. What makes IGF-1 DES unique is what happens before it reaches those receptors. Normal IGF-1 circulates in the bloodstream bound to IGF binding proteins that regulate its activity by controlling how much is available to interact with receptors. In most cases, the majority of IGF-1 in the body is bound and inactive. IGF-1 DES bypasses this regulatory system almost entirely because without the first three amino acids it has very low affinity for IGFBPs, meaning nearly all of it remains free and biologically active.
Once IGF-1 DES binds to the IGF-1 receptor, it activates two primary signaling pathways. The PI3K/Akt/mTOR pathway drives protein synthesis and cell growth. The MAPK pathway promotes cell proliferation and differentiation. Like IGF-1 LR3, IGF-1 DES can activate satellite cells for potential new muscle fiber formation (hyperplasia) in addition to making existing fibers larger (hypertrophy).
The half-life of IGF-1 DES is approximately 20 to 30 minutes, meaning it acts quickly and clears rapidly. This makes it more suitable for localized, site-specific applications. When injected into a specific muscle, the peptide acts locally before being cleared from the system. Research in pigs and marmoset monkeys showed that IGF-1 DES is 2 to 3 times more potent than IGF-1 at lowering blood sugar, confirming that its enhanced bioavailability translates to real physiological effects in living systems.
Potential Benefits
Enhanced Muscle Growth
IGF-1 DES stimulates muscle hypertrophy through direct activation of IGF-1 receptors on muscle fibers. The high bioavailability means more of the peptide reaches muscle tissue to trigger protein synthesis compared to native IGF-1, where most of the hormone is tied up by binding proteins and unavailable.
Satellite Cell Activation
Unlike most anabolic compounds that only increase the size of existing muscle fibers, IGF-1 DES can activate satellite cells, the dormant stem cells responsible for muscle fiber repair and the potential for new muscle cell formation (hyperplasia). This opens the possibility for muscle growth beyond what enlarging existing fibers alone can achieve.
Site-Specific Effects
The short half-life of IGF-1 DES allows for targeted application. When injected into a specific muscle, the peptide acts locally before being cleared from the system within 20 to 30 minutes. This makes it particularly useful for addressing lagging muscle groups that need extra growth stimulus.
Tissue Repair and Recovery
IGF-1 plays a critical role in wound healing and tissue regeneration. IGF-1 DES enhances fibroblast activity and collagen production, supporting repair of muscle, tendon, and other connective tissues. This makes it useful for accelerating recovery from training-induced damage and minor injuries.
Improved Nutrient Uptake
Like its parent compound, IGF-1 DES promotes glucose uptake in muscle tissue. This can improve nutrient partitioning during periods of high caloric intake, helping direct more of the food you eat toward muscle building rather than fat storage.
Neurological Research Applications
IGF-1 DES has shown promise in research on neurological conditions. Studies indicate it may protect synaptic health and neuron density. Clinical trials have explored its use in conditions like Rett syndrome and ALS, suggesting regenerative potential beyond muscle tissue.
Bone Density Support
IGF-1 is essential for bone formation and maintenance. Higher IGF-1 levels correlate with greater bone mineral density, and IGF-1 DES retains these bone-supporting properties with enhanced potency compared to the native hormone.
What the Research Shows
Ballard and colleagues published a foundational study in Biochemical and Biophysical Research Communications in 1987 examining the biological activities and receptor binding of IGF-1 DES. The study found that IGF-1 DES was approximately 10-fold more potent than native IGF-1 at stimulating cell hypertrophy and proliferation. The enhanced potency resulted from greatly reduced binding to IGF binding proteins, and IGF-1 DES retained full affinity for the IGF-1 receptor despite the structural modification.
Tomas and colleagues published a study in the Journal of Endocrinology in 1997 testing IGF-1 variants with poor IGFBP affinity in pigs and marmoset monkeys. IGF-1 DES was 2 to 3 times more potent than IGF-1 at lowering blood sugar, confirming that reduced IGFBP binding translates to greater biological activity in living systems. The enhanced effects extended to anabolic actions on skeletal muscle and neuroprotective properties. A companion study by Ballard and colleagues in the Biochemical Journal showed that binding proteins blocked the growth-promoting activities of IGF-1 and IGF-2, but IGF-1 DES was not affected by these binding proteins.
Clark and colleagues published a study in the Journal of Endocrinology comparing IGF-1 and IGF-1 DES in growth hormone deficient mice. Remarkably, just 3 mcg of IGF-1 DES daily produced growth effects equivalent to 30 mcg of IGF-1, a ten-fold difference in required dose. Total length and nose-rump length increased substantially with IGF-1 DES treatment, and the lower dose increased kidney and heart weights relative to controls. IGF-1 DES has also shown promise in neurological research, with clinical trials exploring its use in conditions like Rett syndrome and ALS.
What to Know
Hypoglycemia (low blood sugar) is the primary concern, causing symptoms like shakiness, sweating, dizziness, and confusion. Always have fast-acting carbohydrates available. Injection site reactions including redness, swelling, or irritation, and mild headache are also common and typically resolve as the body adjusts.
IGF-1 DES may transiently affect insulin sensitivity with repeated use but does not suppress natural testosterone production or affect the hypothalamic-pituitary axis the way anabolic steroids do. No post-cycle therapy is needed when used alone. Running cycles of 4 to 6 weeks followed by equal time off prevents receptor downregulation. Do not exceed 100 mcg total per day.
Do not use if you have active cancer, precancerous conditions or tumors, or uncontrolled diabetes. IGF-1 promotes cell proliferation, and while no studies have proven cancer causation from IGF-1 peptides, individuals with any history of cancer should avoid use due to the mitogenic properties. Use caution with heart conditions as IGF-1 can affect cardiac tissue. Localized tissue overgrowth is a theoretical concern with chronic overuse at specific injection sites.
Research References
Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding
Ballard FJ, Francis GL, Ross M, et al. · Biochemical and Biophysical Research Communications · 1987
Foundational study showing IGF-1 DES is approximately 10-fold more potent than native IGF-1 at stimulating cell hypertrophy and proliferation due to greatly reduced binding to IGF binding proteins while retaining full IGF-1 receptor affinity.
View StudyIGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, Ballard FJ · Journal of Endocrinology · 1997
Demonstrated that IGF-1 DES was 2 to 3 times more potent than IGF-1 at lowering blood sugar in vivo, confirming that reduced IGFBP binding translates to greater biological activity in living systems, with extended effects on skeletal muscle anabolism.
View StudyInsulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1
Ross M, Francis GL, Szabo L, et al. · Biochemical Journal · 1989
Showed that while binding proteins blocked the growth-promoting activities of IGF-1 and IGF-2, IGF-1 DES was completely unaffected by these binding proteins. The biological potencies of different IGF forms correlated inversely with their IGFBP binding.
View StudyIntravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats
Clark RG, Jansson JO, Isaksson O, Robinson IC · Journal of Endocrinology · 1985
Compared IGF-1 and IGF-1 DES in growth hormone deficient mice, finding that just 3 mcg of IGF-1 DES daily produced growth effects equivalent to 30 mcg of IGF-1, demonstrating the ten-fold potency advantage.
View Study